Progression from MCI to mild AD
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Alireza Atri, Liana G Apostolova, Atsushi Iwata, Alette M Wessels, Alexandra Atkins, Ming Lu, Wenyu Ye, Sinéad Ryan, Erin Gautier Doty
Neurol Clin Pract 16(3) e200621
BACKGROUND AND OBJECTIVES: Understanding the meaningfulness of clinical trial outcomes is essential for people living with Alzheimer disease (AD) and their clinicians to make evidence-based shared treatment decisions in real-world clinical care. Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia. This analysis reviews the efficacy of donanemab across various clinical outcome assessments, using both published data and new complementary analyses to provide context on its potential benefits for patients and caregivers. METHODS: We present findings from prespecified and post hoc analyses from the TRAILBLAZER-ALZ 2 trial. Clinical outcomes assessed were Integrated AD Rating Scale (iADRS), comprising the 13-item AD Assessment Scale-Cognitive Subscale (ADAS-Cog13) and AD Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL); Clinical Dementia Rating (CDR)-Sum of Boxes (CDR-SB) for clinical severity and individual cognitive and functional domains; CDR-Global for clinical severity stage progression; meaningful within-patient change (MWPC); and ADCS-Activities of Daily Living dependence score. RESULTS: Donanemab reduced the risk of progression from MCI to mild AD by 33% (hazard ratio [HR] = 0.67; 95% CI 0.52-0.87; p = 0.003) and from mild to moderate AD by 50% (HR = 0.50; 95% CI 0.33-0.78; p = 0.002). In addition, donanemab reduced MWPC risk over 76 weeks by 38% for CDR-SB (HR = 0.62; 95% CI 0.52-0.75; p < 0.001) and 30% for iADRS (HR = 0.70; 95% CI 0.58-0.84; p < 0.001). Donanemab-treated participants exhibited significant slowing of clinical progression across multiple ADAS-Cog13 and ADCS-iADL items and all CDR-SB cognitive and functional domains. Donanemab also slowed progression of dependence least-squares mean change difference, -0.14 [95% CI -0.24 to -0.04; p = 0.007]), representing 23% slowing of progression (95% CI 6.17%-40.32%), and reduced risk of progression to requiring in-home support by 27% (HR = 0.74; 95% CI 0.59-0.91; p = 0.005). DISCUSSION: These results add to the evidence and further support clinically meaningful donanemab-mediated effects on cognition and function for patients and their caregivers and may aid communication of realistic treatment expectations and informed decision-making. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT04437511. Submitted: June 17, 2020; First patient enrolled: June 19, 2020. clinicaltrials.gov/study/NCT04437511 EudraCT Number 2020-000077-25. Start date of recruitment: June 19, 2020. clinicaltrialsregister.eu/ctr-search/trial/2020-000077-25/results.
3 个 Figure · 5 个 KM 面板
Figure 1. Risk of Progression (A) From MCI to Mild AD and (B) From Mild to Moderate AD With Donanemab vs Placebo as Measured by the CDR-G An event was defined as an increase from baseline in the CDR-G score at 2 consecutive visits. The HR, 95% CI ,and p value were calculated using a Cox proportional hazards model that included covariates of baseline age and baseline acetylcholinesterase inhibitor/memantine use, which was stratified by baseline tau category and pooled investigator. The overall population is defined as the low-medium and high-tau populations. AD = Alzheimer disease; CDR-G = Clinical Dementia Rating scale–Global; HR = hazard ratio; MCI = mild cognitive impairment.
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel B
Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. Risk of MWPC Over 76 Weeks With Donanemab vs Placebo as Measured by the (A) CDR-SB and (B) iADRS An event was defined as an MWPC from baseline in the CDR-SB or iADRS score at 2 consecutive visits. The HR, 95% CI and p value were calculated using a Cox proportional hazards model that included covariates of baseline age, baseline value, and baseline acetylcholinesterase inhibitor/memantine use, which was stratified by pooled investigator and baseline tau level. Ties in event times were handled using the discrete method, as the trial measurements were collected at scheduled visits and the exact event times were unknown. MWPC for the CDR-SB was defined as change of ≥1 point for MCI due to AD and ≥2 points for mild dementia due to AD at 2 consecutive visits from baseline. MWPC for the iADRS was defined as a change of ≥5 points for MCI due to AD and ≥9 points for mild dementia due to AD, respectively, at 2 consecutive visits. The analysis used the first event for modeling. The overall population is defined as the low-medium and high tau populations. AD = Alzheimer disease; CDR-SB = Clinical Dementia Rating scale–Sum of Boxes; HR = hazard ratio; iADRS = Integrated Alzheimer’s Disease Rating Scale; MCI = mild cognitive impairment; MWPC = meaningful within-patient change.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. Change From Baseline in the Dependence Score by (A) Treatment and (B) Time to the Need for Frequent In-Home Support (DS ≥ 3) *Baseline mean (SD) DS: placebo, 1.97 (0.93); donanemab, 1.99 (0.99). ADCS-ADL = Alzheimer’s Disease Cooperative Study–Activities of Daily Living Inventory; BL = baseline; DS = dependence score; HR = hazard ratio; LS = least squares; M = month; SE = standard error.
Figure 4 · Panel B
Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。